---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-049232"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2026-07-22T21:17:19+00:00"
generated_at: "2026-07-22T21:20:06.240851+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Repligen to acquire BioLife for $1.5B enterprise value, $31.00 per share

## Summary
- Repligen to acquire BioLife for $31.00/share (0.1442 RGEN shares + $11.25 cash); total enterprise value ~$1.5B.
- Transaction expected to close in Q4 2026, subject to BioLife stockholder approval and regulatory clearances.
- BioLife reports preliminary Q2 revenue growth ~21% YoY; Repligen reports preliminary Q2 revenue growth ~12-13% organic.
- Deal expected to be accretive to Repligen's adjusted EPS by at least $0.05 in year one and at least $0.25 in year two.
- Termination fee of $59M payable by BioLife under certain circumstances if deal fails.

## SEC filing metadata
- accession: 0001628280-26-049232
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2026-07-22T21:17:19+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000162828026049232/0001628280-26-049232-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000162828026049232/blfs-20260721.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-049232
- JSON: https://secwatch.observer/filing/0001628280-26-049232.json
- Plain text: https://secwatch.observer/filing/0001628280-26-049232.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.